Palisade Bio (PALI) announced the presentation of positive preclinical data from PALI-2108, an orally administered, colon-specific ...

Carlsbad, CA, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc, (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage ...

Session: Poster and Exhibition Hall Reception Poster Title:PALI-2108, a Colon-Specific PDE4B Inhibitor Prodrug is Activated in the Colon and Reduces Ulcerative Colitis Symptoms in an Acute Colitis DSS ...

US-based biopharmaceutical company Palisade Bio has begun the multiple ascending dose (MAD) cohorts of its ongoing Phase Ia/b trial of PALI-2108 for treating ulcerative colitis (UC). These cohorts ...

Palisade Bio, Inc. announced positive preliminary findings from its ongoing Phase 1a/b clinical study of PALI-2108, a treatment for Ulcerative Colitis (UC), indicating high tolerability and safety ...

For more information about Webull, visit www.webull.com. Palisade Bio is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with ...

Palisade Bio is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases.